Navigation Links
Carnegie Mellon researchers receive grant
Date:12/9/2009

PITTSBURGHCarnegie Mellon University's Yoed Rabin and Kenji Shimada have received a four-year, $1.3 million grant from the National Cancer Institute to develop computerized training tools for cryosurgery, which is the destruction of undesired tissue, such as cancerous tumors and organs, by freezing.

At present, minimally invasive cryosurgery, such as prostate cryosurgery, is performed by inserting cryoprobes in the shape of long hypodermic needles with a cooling tip into the tumor. Cryoprobes placement and the following process of freezing are monitored by an imaging technique, such as ultrasound or MRI.

Mechanical engineering professors Rabin and Shimada are developing an interactive simulator for the entire cryosurgical procedure, combined with a computerized tutor to evaluate the quality of simulated clinical cases.

"This is a revolutionary concept of enhancing surgical training by practicing a virtual cryosurgical procedure," said Rabin, who is leading this project and is an expert in biothermal technology.

Rabin has been developing cryosurgical devices, research techniques and training methods for the past 18 years.

"While we have already developed rapid computer simulation techniques for cryosurgery and algorithms to help make better cryosurgery planning decisions, the challenge in the current project is to develop an interactive tool, which is capable of evaluating and comparing varying surgical scenarios," Rabin said.

"It is like a video game. With our computerized training system, surgeons will be able to try out various cryoprobe placements without risk, visualize frozen regions with intuitive 3D computer graphics, and benchmark their performance with hundreds of cases stored in a database. It is a motivational and effective way of learning and improving their surgical skills," said Shimada, who is an expert in computational modeling and simulation for product design, engineering analysis and factory automation.

While the developed computerized training tools are potentially applicable to all cryosurgical procedures, the current project is aimed at prostate cancer.

The American Cancer Society estimates that 192,280 new cases of prostate cancer will be diagnosed in the United States in 2009. Prostate cancer is the second leading cause of cancer death in men, exceeded only by lung cancer. One in six men will get prostate cancer during his lifetime, and one in 35 will die of this disease.

Minimally invasive cryosurgery is one of the established applications to treat prostate cancer.

"The combination of traditional training techniques with cost-effective computerized training tools can potentially be of high impact on the quality and cost of the cryosurgical treatment, and I am committed to its development and integration," Rabin said.


'/>"/>

Contact: Chriss Swaney
swaney@andrew.cmu.edu
412-268-5776
Carnegie Mellon University
Source:Eurekalert

Related biology news :

1. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
4. Carnegie Mellon, Pitt Team to study psychosocial stress
5. Mellon awards Carnegie Grant for Ecological Monitoring in South Africa
6. Carnegie Mellon researchers to develop new drug delivery system
7. Carnegie Mellon students win contest
8. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
9. U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica
10. Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design
11. Carnegie Mellon receives $1.85 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... ... announced that it has submitted a 510(k) to the FDA, requesting clearance of ... patent-pending functional electrical stimulation (FES) technology. , The submission marks a major ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, ... panel discussions to examine vital clinical research issues such as trial performance metrics, ...
(Date:1/18/2017)... ... 18, 2017 , ... uBiome, the leading microbial genomics company, ... Editor, Dr. Elisabeth Bik, in the December 2016 issue of the Dutch Journal ... October 2016 from her previous position at Stanford University School of Medicine and ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
Breaking Biology Technology: